Veterinary Biomarkers Market Analysis

Veterinary Biomarkers Market Analysis

To get key market trends

  Download Free Sample

Based on the animal type, the market is categorized as companion animals and livestock animals. The companion animal segment is set to lead the market, accounting for the largest revenue of USD 523.5 million in 2023, anticipating its dominance throughout the forecast period. The companion animal segment is further categorized into dogs, cats, horses, and other companion animals.
 

• The segment’s dominance is driven by the significant role of biomarkers in diagnosing and managing health conditions in pets such as dogs and cats.
   
• Biomarkers enable early detection, monitoring of treatment responses, and personalized care, contributing to improved animal health outcomes.
   
• The segment's leadership is bolstered by increasing pet ownership rates, rising expenditures on pet healthcare, and advancements in veterinary diagnostics tailored for companion animals.
   
• For example, NAPHIA reported that in 2022, the U.S. and Canada together had 5.4 million insured companion animals, a 22% rise from the 4.4 million in 2021. This surge in insured pets, driven by favorable insurance policies, not only boosts pet adoption rates but also escalates the demand for advanced healthcare services, consequently expanding the adoption of biomarker tests and diagnostic services.
   

Based on product type, the veterinary biomarkers market is classified into biomarkers readers and biomarkers kits & reagents. The kits & reagents segment held the largest market share of 62% in 2023 and is expected to maintain dominance throughout the analysis period.

• Veterinarians prioritize sensitive and precise diagnostic approaches facilitated by biomarker test kits. These kits are crucial for tracking disease progression and administering targeted treatments based on biological indicators.
   
• For instance, as reported in MDPI in August 2022, biomarkers show promise in accelerating disease diagnosis, monitoring animal health impacts, and enhancing animal welfare and productivity, potentially revolutionizing veterinary practice. Moreover, cardiac biomarkers like pro-BNP and cardiac troponin I (cTnI) play a critical role in diagnosing and treating progressive cardiac disorders in companion animals, as highlighted in Acta Scientific in June 2022. This increasing adoption of biomarkers for disease diagnosis and treatment in animals is a key driver of segment growth.
   
• Moreover, increasing awareness of biomarker applications in veterinary medicine, particularly in developing countries, has contributed significantly to market expansion in recent years.
   

Based on the disease type, the veterinary biomarkers market is segmented into inflammatory and infectious diseases, cardiovascular diseases, renal diseases, cancer, and other disease type. The inflammatory and infectious diseases segment dominated the market anticipating its dominance throughout the forecast period with a CAGR of 9.8%.
 

• The segment dominance stems from its crucial role in diagnosing and monitoring conditions such as canine parvovirus, feline leukemia, and diverse bacterial infections.
   
• The specific biomarkers for these diseases facilitate early detection, assessment of treatment effectiveness, and effective disease management.
   
• Thus, the significance of precise and prompt diagnostic tools in veterinary medicine, ultimately improving animal health outcomes through targeted therapeutic approaches, which are in high demand among veterinarians and pet owners.
   

Based on the application, the veterinary biomarkers market is segmented into clinical and research. The clinical segment is projected to reach 78.1% by 2032. The clinical segment is further categorized into disease diagnosis and disease monitoring.

• The clinical application segment dominance is driven by its key role in disease diagnosis, treatment monitoring, and prognosis assessment across various animal species. Biomarkers facilitate early diagnosis and precise monitoring of diseases such as cancer, cardiovascular conditions, and infectious diseases in animals.
   
• In addition, the segment's growth is propelled by advancements in biomarker technologies, increasing demand for accurate diagnostic tools, and the expanding adoption of personalized veterinary medicine practices globally.
   

Based on the end-user, the veterinary biomarkers market is segmented into veterinary hospitals, veterinary clinics, research institutes, and reference laboratories. The veterinary clinics segment dominated the market with the highest share in 2023.
 

• Veterinary clinics play a pivotal role in diagnosing and treating animal health issues. They heavily rely on biomarkers for early disease detection, treatment monitoring, and overall health management in animals.
   
• The veterinary clinic segment's significance is propelled by a surge in pet ownership, growing awareness of veterinary care, and technological advancements in diagnostics that bolster clinic capabilities.
   

U.S. dominated the North American veterinary biomarkers market accounting for USD 333.4 million in 2023 and is anticipated to show considerable growth over the analysis period.
 

• The U.S. has the highest rates of pet ownership globally, with over 66% of American households owning dogs or cats. This large companion animal population, coupled with high annual spending on veterinary care (averaging USD 912 per dog and USD 653 per cat), expects to fuel demand for advanced diagnostic solutions thereby expanding the adoption of biomarker-based tests.
   
• Additionally, the presence of major market players like IDEXX Laboratories, Zoetis, and Merck & Co. which are investing heavily in R&D has enabled the development of innovative biomarker products.
   
• Furthermore, the robust regulatory framework from the FDA that supports clinical trials and ensures high quality standards has further bolstered the U.S. market's growth and innovation in veterinary diagnostics.
   
• These factors have collectively positioned the U.S. as the largest market for veterinary biomarkers in North America.
   

Germany exhibited a high growth potential in the European veterinary biomarkers market.
 

• Germany's prominence is driven by its robust animal healthcare infrastructure, stringent regulations around animal welfare, and high pet ownership rates.
   
• According to a recent report from the Central Association of Zoological Specialist Companies (ZZF), a German pet trade and industry association, pets are extremely popular in Germany. In 2023, German households were home to a total of 34.3 million dogs, cats, small animals, and pet birds. This large companion animal population, coupled with the German government's focus on advancing veterinary diagnostics, aimed to fuel the demand for innovative biomarker-based testing solutions in the country.
   
• Additionally, key players in the market have responded to the growing trend of pet humanization by establishing manufacturing and R&D facilities in Germany. This strategic shift allows them to cater to the increasing demand for innovative biomarker-based testing solutions in the country.
   

The Asia Pacific veterinary biomarkers market is poised for rapid growth with a CAGR of 10.4% during the forecast period.
 

• The Asia Pacific market is set for rapid expansion driven by higher pet ownership rates, increased awareness of animal health, and rising prevalence of chronic diseases.
   
• The economic growth and improved access to advanced veterinary care also play significant roles in this growth
  .
• Moreover, government initiatives promoting animal health and investments in veterinary infrastructure are further bolstering market growth.
   
• As a result, the region's burgeoning veterinary diagnostics sector underscores robust demand for comprehensive and dependable in-vitro diagnostic solutions including biomarkers in the market.